evaluated the impact of baseline PSA and metastatic substages on the survival benefit of LTs vs. NLTs for mPCa based on SEER and found that a survival benefit existed for patients with M1b PCa, but not for those with M1c PCa (21). The gene discussed is KLK3; the disease is posterior cortical atrophy.